Discover scalable, innovative therapies for obesity. Our next-gen NuSH treatments offer effective, convenient solutions to empower lasting weight loss. Learn more today!

1 day ago · At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...

Jan 7, 2025 · Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.

Sep 24, 2024 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to...

In the study, MET-097i demonstrated competitive and durable weight loss, including 7.5% reduction in body weight from baseline at day 36. MET- 097i, incorporating our HALO platform technology, showed an approximate 380-hour half-life, supporting the potential for once-monthly dosing and dosing regimens without titration.

Jan 7, 2025 · Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some of its $215 million war chest to assess monthly dosing of the...

Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

Sep 24, 2024 · Five months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech said the results were as good as or better than approved or other similar clinical-stage GLP-1 compounds out there now.

Sep 24, 2024 · Metsera's Phase 1 trial of MET-097, a long-acting GLP-1 receptor agonist, demonstrated a 7.5% reduction in body weight from baseline at day 36. The drug's 380-hour half-life suggests the possibility for once-monthly dosing without titration, offering a more convenient and scalable treatment option.

Jan 7, 2025 · Months after posting weight loss of 7.5 percent at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11 percent average body weight reduction at 12 weeks, with no plateau and a promising safety profile.